1st Quarter - Report

BALLARD SPAHR LLP for CENCORA, INC.

Firm
Client
Income
$20,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection. International Pricing Index Model.

LobbyistCovered position, as disclosed
TIMOTHY W JENKINS —
SHERRY HARPER WIDICUS Legislative Assistant and Legislative Director, Rep. Kind

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress).

LobbyistCovered position, as disclosed
TIMOTHY W JENKINS —
SHERRY HARPER WIDICUS Legislative Assistant and Legislative Director, Rep. Kind

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 803 (116th), H.R. 6600 (116th), S. 3282 (116th), S. 988 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.